Megestrol Acetate and olanzapine

Phase 3Small molecule

Megestrol Acetate and olanzapine is one of 48 small molecule programs targeting Immunotherapy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

ImmunotherapyRecruiting

ImmunotherapyPhase 3

Recruiting

Competition

Competitive Landscape

77 competitors in Immunotherapy

#DrugCompanyPhaseTrials

Opdivo

Bristol-Myers Squibb

Phase 3

21 2

Keytruda

Merck & Co.

Phase 3

16 3

Tecentriq

Roche

Phase 3

8 4

Taxol

Teva

Phase 3

3 5

Paraplatin

AAvyxa

Phase 3

6 6

Yervoy

Bristol-Myers Squibb

Phase 2

8 7

Imfinzi

AstraZeneca

Phase 2

5 8

Herceptin

Roche

Phase 2

4 9

Abraxane

Bristol-Myers Squibb

Phase 2

3 10

Eloxatin

Teva

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 3Recruiting

Immunotherapy

NCT06500234

Clinical

Trials by Indication[1]

Immunotherapy1 trial

Nutrition Impact on Immunotherapy of Cancer

Recruiting·QQingdao Central Hospital·Phase 3·NCT06500234·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Megestrol Acetate and olanzapine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Megestrol Acetate and olanzapine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Megestrol Acetate and olanzapine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Qingdao Central Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: QQingdao Central Hospital

Megestrol Acetate and olanzapine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Immunotherapy1 trial

References

Drug Info

Quick Facts

Related News